AKTX

Akari Therapeutics Plc (AKTX) - Q2 2024 10-Q Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended June 30, 2024. Akari Therapeutics Plc is a biotechnology company focused on developing advanced therapies for autoimmune and inflammatory diseases. The company is currently in a pre-commercial stage with no product revenue. Key strategic developments in the quarter include the suspension of its HSCT-TMA clinical program, a significant workforce reduction, and ongoing preparations for a planned merger with Peak Bio, Inc., expected to close in Q4 2024.

Key Financial Metrics

Note: All figures in millions unless otherwise noted. The company reported no revenue for any period presented.

Material Changes vs. Prior Period

• Increased Operating Loss: Net loss for the six months ended June 30, 2024, increased to $13.1 million from $3.0 million in the same period in 2023. This was driven by higher Research and Development (R&D) expenses and new one-time costs.
• Restructuring Costs: The company incurred $1.6 million in restructuring and other costs in Q2 2024, primarily related to a reduction-in-force (RIF) of approximately 67% of its workforce. No such costs were incurred in 2023.
• Merger-Related Costs: $1.3 million in merger-related costs were recorded for the six months ended June 30, 2024, compared to none in 2023.
• R&D Expense Fluctuation: R&D expenses increased to $5.6 million (YTD 2024) from $3.3 million (YTD 2023), largely due to manufacturing and development activities for PAS-nomacopan, partially offset by the suspension of the HSCT-TMA program.
• Warrant Liability: The company recorded a non-cash gain of $0.5 million on the change in fair value of warrant liability for the six months ended June 30, 2024, compared to a $6.1 million gain in the prior year period.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern Warning: Management has concluded there is substantial doubt about the company's ability to continue as a going concern within one year of the report date. Cash of $4.2 million is insufficient to fund operations for the next 12 months without additional financing.
• Liquidity and Financing: The company raised approximately $9.3 million in net proceeds during the first half of 2024 through private placements and convertible notes. Closing of the Peak Bio merger is contingent on a PIPE investment of at least $10 million.
• Nasdaq Compliance: The company is not in compliance with Nasdaq's minimum shareholders' equity requirement ($2.5 million), reporting a deficit of $3.7 million. An extension to regain compliance has been granted until September 30, 2024.
• Strategic Shift: Following a portfolio review, the HSCT-TMA program was suspended. Future focus will be on PAS-nomacopan for Geographic Atrophy (GA) and Peak Bio's ADC platform post-merger.
• Unusual Items: The $1.6 million restructuring charge included $1.3 million in severance and $0.3 million in accelerated equity vesting. Merger-related costs of $1.3 million were also significant non-recurring expenses.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $4.2 million cash balance against the stated need for additional capital to fund operations into Q4 2024.
• Merger Conditions: Confirm the status of the $10 million PIPE investment required to close the Peak Bio merger and the timeline for the S-4 registration statement.
• Nasdaq Listing Status: Monitor the company's ability to meet the $2.5 million shareholders' equity requirement by the September 30, 2024 deadline to avoid delisting.
• Restructuring Execution: Assess whether the 67% workforce reduction has achieved the intended cost savings and if the remaining staff is sufficient to execute the PAS-nomacopan program.
• Debt Obligations: Review the terms of the $1.0 million convertible notes issued to related parties (due Nov 2024 or upon tax credit receipt) and the short-term insurance financing arrangement.